Dr. Jennifer Chheda has over 20 years of experience developing, implementing, and managing worldwide patent portfolios covering commercial biologics and pharmaceuticals as well as products in development, including clinical candidates. She has developed patent strategies for marketed products, such as Synagis®, Auryxia®, Talymed®, and Translarna™, and products in development, including, for example, Crenezumab. Jennifer has worked with pioneers developing vaccines, such as a universal influenza virus vaccine, and virus-based cancer vaccines. Furthermore, she has evaluated patent portfolios and prosecuted patent applications relating to enzyme replacement therapy, RNA therapeutics, gene therapy, antibodies, antibody drug conjugates, and cell-based therapies (for example, CAR-T cells).
Jennifer's experience also includes patentability, invalidity, noninfringement, freedom-to-operate, and inventorship analyses and conducting due diligence for potential investors, acquirers, and licensees, such as venture capital firms, biotechnology companies, and pharmaceutical companies.
Jennifer has provided strategic advice to clients regarding Patent Trial and Appeal Board (PTAB) proceedings, such as inter partes review, interferences, and reexaminations, and other post-grant proceedings, such as oppositions and invalidity actions. In addition, she has patent litigation experience that includes coordinating worldwide litigations, drafting expert reports, and preparing experts for trial.
Jennifer also has experience drafting and negotiating intellectual property agreements, including license, sponsored research, and development agreements. She has provided IP advice in the context of M&A transactions and has advised clients such as AbbVie, REGENXBIO, and Celgene in IP-related transactions.
Patent Prosecutors Beware: Earlier Publication Anticipates Broad Claims of Continuing Application, PTAB Litigation Blog
- April 9, 2016
PharmaDJ Roundtable Discussion on Biosimilar and Antibody Development: Options for Asian Biosimilar Companies in the U.S.
- October 28, 2010
The Advent of Biosimilars: What you (and your clients) should know
- New York Law School (J.D. 2002); New York University (Ph.D. in Microbiology 1999; M.Sc. in Microbiology 1994); University of Connecticut (B.S. in Molecular and Cellular Biology cum laude 1992)
- New York and registered to practice before the United States Patent and Trademark Office